Fatih Mehmet KANDEMİR, Mustafa Sinan AKTAŞ, Sefa KÜÇÜKLER, Başak HANEDAN, Cüneyt ÇAĞLAYAN

Ratlarda Sisplatinden Kaynaklanan Nefrotoksisite Üzerine Rutinin İyileştirici Etkileri

Solid tümörü olan hastalarda sisplatin tedavisi yaygındır, fakat kullanımını sınırlandıran önemli bir faktör nefrotoksik etkileridir. Dolayısıyla bu çalışma ratlarda sisplatinden kaynaklanan nefrotoksisitede oksidatif stres, apoptotik protein kaspaz-3 ve antiapoptotik protein Bcl-3 düzeyleri üzerine rutinin etkilerini değerlendirmek amacıyla yapıldı. Ratlar rastgele 3 gruba ayrıldı (her grupta 7 adet rat). Grup I’e serum fizyolojik uygulandı. Grup II’ye çalışmanın 10. gününde periton içi sisplatin uygulandı. Grup III’e 14 gün boyunca 150 mg/kg ağızdan rutin ve çalışmanın 10. gününde 10 mg/kg periton içi sisplatin uygulandı. Üre, kreatinin, malondialdehit (MDA), glutatyon (GSH), süperoksit dismutaz (SOD), katalaz, glutatyon peroksidaz (GSH-Px), kaspaz-3 ve B-hücre lenfoma protein 3 (Bcl-3) düzeylerinin ölçülmesi için böbrekler ve kan örnekleri toplandı. Ratlarda tek doz sisplatin uygulanması böbrek hasarına neden oldu. Rutin, antioksidant aktiviteyi artırarak ve MDA, kaspaz-3 ve Bcl-3 düzeylerini azaltarak nefrotoksisiteyi önemli düzeyde azalttı (P

Ameliorating Effects of Rutin on Nephrotoxicity Caused by Cisplatin in Rats

Cisplatin treatment in patients with solid tumor is common, but a major factor limiting its use isnephrotoxic effects. Thus, this study was performed to investigate the effects of rutin on oxidativestress, apoptotic protein caspase-3 and anti-apoptotic protein Bcl-3 levels in nephrotoxicity causedby cisplatin in rats. The rats were randomly separated into three groups (7 rats in each group).Group I was treated with physiological saline. Group II was treated with cisplatin intraperitoneallyon the tenth day of the study. Group III was treated with rutin 150 mg/kg orally for 14 days pluscisplatin 10 mg/kg intraperitoneally on the tenth day of the study. The kidneys and blood sampleswere collected for the measurement of urea, creatinine, malondialdehyde (MDA), glutathione(GSH), superoxide dismutase (SOD), catalase, glutathione peroxidase (GSH-Px), caspase-3 andB-cell lymphoma protein 3 (Bcl-3) levels. Single dose cisplatin treatment in the rats caused thekidney injury. Rutin alleviated nephrotoxicity by significantly increasing antioxidant activity, anddecreasing MDA, caspase-3 and Bcl-3 levels (P

PDF

___

1. Bergamini A, Pisano C, Di Napoli M, et al. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecol Oncol 2017; 144: 72-76.
2. Chen X, Zou H, Li H, et al. Weekly versus triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of cervical cancer: A Metaanalysis. Int J Gynecol Cancer 2017; 27: 344-349.
3. Guidi A, Codeca C, Ferrari D. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol 2018; 35: 37.
4. Ma Y, Zhang NP, An N, et al. Clinical efficacy of weekly cisplatin for treatment of patients with breast cancer. Medicine (Baltimore) 2019; 98: e17114.
5. Kosmidis C, Sapalidis K, Zarogoulidis P, et al. Inhaled Cisplatin for NSCLC: Facts and Results. Int J Mol Sci 2019; 20: pii: E205.
6. Hu Z, Yu J, Gui G, et al. Cisplatin for testicular germ cell tumors: a rapid review. J Evid Based Med 2016; 9: 144- 151.
7. Zhou X, Ling K, Liu M, et al. Targeted delivery of cisplatinderived nanoprecursors via a biomimetic yeast microcapsule for tumor therapy by the oral route. Theranostics 2019; 9: 6568-6586.
8. Manohar S, Leung N. Cisplatin nephrotoxicity: A review of the literature. J Nephrol 2018; 31: 15-25.
9. Hamroun A, Lenain R, Bigna JJ, et al. Prevention of cisplatin-induced acute kidney injury: A systematic review and meta-analysis. Drugs 2019; 79: 1567-1582.
10. Kuhlmann MK, Burkhardt G, Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997; 12: 2478-2480.
11. Yang Y, Liu H, Liu F, Dong Z. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity. Arch Toxicol 2014; 88: 1249-1256.
12. Tanabe K, Tamura Y, Lanaspa MA, et al. Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy. Am J Physiol-Renal Physiol 2012; 303: F1264-1274.
13. Kharbangar A, Khynriam D, Prasad SB. Effect of cisplatin on mitochondrial protein, glutathione, and succinate dehydrogenase in Dalton lymphoma-bearing mice. Cell Biol Toxicol 2000; 16: 363-373.
14. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994- 1007.
15. Ganeshpurkar A, Saluja AK. The pharmacological potential of rutin. Saudi Pharm J 2017; 25: 149-164.
16. Hosseinzadeh H, Nassiri-Asl M. Review of the protective effects of rutin on the metabolic function as an important dietary flavonoid. J Endocrinol Invest 2014; 37: 783-788.
17. Kandemir FM, Ozkaraca M, Yildirim BA, et al. Rutin attenuates gentamicin-induced renal damage by reducing oxidative stress, inflammation, apoptosis, and autophagy in rats. Ren Fail 2015; 37: 518-525.
18. Caglayan C, Kandemir FM, Darendelioglu E, et al. Rutin ameliorates mercuric chloride-induced hepatotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis. J Trace Elem Med Biol 2019; 56: 60-68.
19. Caglayan C, Kandemir FM, Yildirim S, Kucukler S, Eser G. Rutin protects mercuric chloride-induced nephrotoxicity via targeting of aquaporin 1 level, oxidative stress, apoptosis and inflammation in rats. J Trace Elem Med Biol 2019; 54: 69-78.
20. Aksu EH, Kandemir FM, Ozkaraca M, Omur AD, Kucukler S. Rutin ameliorates cisplatin-induced reproductive damage via suppression of oxidative stress and apoptosis in adult male rats. Andrologia 2017; 49: e12593.
21. Enogieru AB, Haylett W, Hiss DC, Bardien S, Ekpo OE. Rutin as a potent antioxidant: Implications for neurodegenerative disorders. Oxid Med Cell Longev 2018; 2018: 6241017.
22. Yang H, Wang C, Zhang L, Lv J, Ni H. Rutin alleviates hypoxia/reoxygenation-induced injury in myocardial cells by up-regulating SIRT1 expression. Chem Biol Interact 2019; 297: 4-49.
23. Placer ZA, Cushman LL, Johnson BC. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem 1966; 16: 359-364.
24. Aebi H. Catalase. In: Bergmeyer H (Editor). Methods in Enzymatic Analysis. New York: Academic Press. 1974; 276-286.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
26. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497- 500.
27. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968; 25: 192-205.
28. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976; 71: 952-958.
29. Sümbüloğlu K, Sümbüloğlu V. Biyoistatistik. 6. Baskı, Ankara: Özdemir Basım, Yayım ve Dağıtım Ltd. Şti, 1995.
30. Qin X, Meghana K, Sowjanya NL, et al. Embelin attenuates cisplatin-induced nephrotoxicity: Involving inhibition of oxidative stress and inflammation in addition with activation of Nrf-2/Ho-1 pathway. Biofactors 2019; 45: 471-478.
31. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001; 12: 2683-2690.
32. Kadikoylu G, Bolaman Z, Demir S, et al. The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 2004; 23: 29-34.
33. Arjumand W, Seth A, Sultana S. Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NFkappaB, TNF-alpha and caspase-3 expression in wistar rats. Food Chem Toxicol 2011; 49: 2013-2021.
34. Kandemir FM, Yildirim S, Caglayan C, Kucukler S, Eser G. Protective effects of zingerone on cisplatin-induced nephrotoxicity in female rats. Environ Sci Pollut Res Int 2019; 26: 22562-22574.
35. Malik S, Suchal K, Gamad N, Dinda AK, Arya DS. Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis. Eur J Pharmacol 2015; 748: 54-60.
36. Nazari Soltan Ahmad S, Rashtchizadeh N, Argani H, et al. Tangeretin protects renal tubular epithelial cells against experimental cisplatin toxicity. Iran J Basic Med Sci 2019; 22: 179-186.
37. Ko JW, Shin NR, Jung TY, et al. Melatonin attenuates cisplatin-induced acute kidney injury in rats via induction of anti-aging protein, Klotho. Food Chem Toxicol 2019; 129: 201-210.
38. Qu S, Dai C, Lang F, et al. Rutin attenuates vancomycininduced nephrotoxicity by ameliorating oxidative stress, apoptosis, and inflammation in rats. Antimicrob Agents Chemother 2019; 63: e01545-18.
39. Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH. Negative regulation of toll-like receptor signaling by NFkappaB p50 ubiquitination blockade. Science 2007; 317: 675-678.
40. Collins PE, Kiely PA, Carmody RJ. Inhibition of transcription by B cell leukemia 3 (Bcl-3) protein requires interaction with nuclear factor kappaB (NF-kappaB) p50. J Biol Chem 2014; 289: 7059-7067.
41. Poveda J, Sanz AB, Carrasco S, et al. Bcl3: A regulator of NF-kappaB inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells. Exp Mol Med 2017; 49: e352.